Par'Immune
Société
1
abonné
Onglets principaux
À propos de votre organisation / profil
Par’Immune is a biopharmaceutical company developing the parasite derived P28GST protein as immunotherapeutic platform in autoimmune and inflammatory diseases.
Besides its protective role in experimental schistosomiasis, the immunomodulatory potential of P28GST has been validated in preclinical models of Inflammatory Bowel Disease and a Phase 2a clinical trial is ongoing in Crohn’s disease.
During 2018, the company will initiate Phase 2 clinical trails both in IBD ans psoriasis.
The company was founded in October 2017 by a well known scientific and business team.
Réseau (0)
Il n'y a pas encore d'organisations dans le réseau.
Cette organisation ne comporte pas d'utilisateur pour le moment.
